Expert Interview
Discussing Ascendis Pharma A/S’ TransCon hGH for Pediatric Growth Hormone Deficiency, as it receives EMA approval
Ticker(s): ASNDA pediatric endocrinologist with experience in treating Pediatric Growth Hormone Deficiency.
Please tell us about your clinical experience. How many patients with hATTR Amyloidosis do you see on a yearly basis? Could you talk about the standard of care for GHD - the daily subcutaneous injection of hGH?
Added By: slingshot_insightsWhat % of patients achieve good outcomes with standard of care medication?
Added By: slingshot_insightsWhat advantages do TransCon molecules have? Can you tell us in detail about the interactions of the three components: unmodified parent drug, inert carrier that protects it, and a linker that temporarily binds the two?
Could you please comment on the company’s Phase 3 heiGHt, fliGHt and enliGHten Trials, how convinced are you by the results?
How likely are you to switch patients to Ascendis’ prodrug somatropin formulation? How important is the sustained release of unmodified somatropin (hGH) at predictable therapeutic levels in the body in achieving better outcomes to your patients?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
